Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells.

Litjens NHR, Jonker J, Klepper M, Prevoo F, Hesselink DA

RANDOMIZED CONTROLLED TRIAL Tier 2 2026

DesignRANDOMIZED CONTROLLED TRIAL

TierTier 2, Strong human evidence, hard endpoints or biomarkers

Year2026

JournalFrontiers in immunology

Published2026

Added to NO1GEVITYAug 20, 2026

Cited by

1 encyclopedia entries reference this study.